ProSomnus Inc’s next-generation remote patient monitoring device for obstructive sleep apnea (OSA), RPMO2 OSA, demonstrated in a pilot study that an oximeter embedded in an oral appliance can accurately, safely, and continuously monitor blood oxygen saturation (SpO2).

An intraoral medical device capable of performing remote patient monitoring of physiologic parameters relevant to OSA, such as arterial oxygen saturation and pulse rate, would enable healthcare providers to monitor the residual risks associated with any OSA treatment. 

Few treatments for OSA offer the healthcare provider real-time information about treatment status. Even fewer, if any, offer the healthcare provider access to metrics predictive of cardiovascular morbidity and mortality, such as sleep apnea-specific hypoxic burden or sleep apnea-specific pulse rate response, according to a release from ProSomnus. The calculation of such predictive metrics requires, at minimum, full-night pulse oximetry.

For the study, healthy adult volunteers were fitted with a ProSomnus RPMO2 OSA Device and a US Food and Drug Administration (FDA)-cleared reference oximeter. Each volunteer then underwent a standard controlled desaturation protocol in accordance with FDA and medically accepted parameters to achieve six desaturation plateaus between 70% and 100% SaO2. 

Five matched data pairs between the ProSomnus RPMO2 and FDA-cleared reference oximeter from each desaturation plateau were pooled to determine the accuracy of the ProSomnus RPMO2 Device. Based on the FDA’s requirements for accuracy, a performance goal of root mean square error of less than 3.5% was selected.

Eighty-five matched data pairs were included in the analysis. The root mean square error for the ProSomnus RPMO2 OSA Device was 2.32%. The minimum and maximum SpO2 values recorded by the ProSomnus RPMO2 OSA Device were 71.8% and 100%, respectively. Bland-Altman analysis showed a bias of 0.24 and lower and upper 95% limits of agreement of -4.31 and 4.79, respectively.

“Pilot testing was a crucial step in the development and preliminary validation of the ProSomnus RPMO2 OSA Device,” says Erin Mosca, PhD, director of scientific and medical affairs for ProSomnus Sleep Technologies, in a release. “The results of the pilot testing hold tremendous promise for the formal validation testing, in which the ProSomnus RPMO2 OSA Device will be compared against a gold standard.”

John E. Remmers, MD, chief scientist for ProSomnus Sleep Technologies, adds in a release, “The results of our pilot studies are impressive and demonstrate that ProSomnus has the capability to implement an intraoral oximeter. We believe that this technology, following further validation testing and obtaining the necessary regulatory approvals, has the potential to meaningfully advance the role of oral appliances in treating OSA. Oxygen monitoring provides ongoing assessment of the efficacy of oral appliance therapy.”

Photo 167081308 © Tulipdesign18 |